About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, October 18th, 2013

The QualityStocks
Daily Stock List


Senesco Technologies, Inc. (SNTI)

Today we are reporting on Senesco Technologies, Inc. (SNTI), here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, Senesco Technologies, Inc. is a leader in eIF5A technology. The foundation of their platform technology is on the discovery that eIF5A (Factor 5A), a gene that is highly conserved from plants to people, can regulate programmed cell death (apoptosis) and cell survival through controlling the expression of pro-apoptotic and anti-apoptotic proteins. Senesco Technologies has their headquarters inBridgewater, New Jersey.

The Company’s current focus in Therapeutics is on cancer. Moreprecisely, it is on multiple myeloma (MM) and other B-cell cancers including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL). SNS01-T has been shown to inhibit the growth and even shrink tumors in animal models of human B-cell cancers. This includes multiple myeloma, mantle cell lymphomia, and diffuse large b-cell lymphoma. SNS01-T has been granted orphan drug status by the US Food and Drug Administration (FDA).

Senesco Technologies is sponsoring a clinical study with their lead therapeutic candidate SNS01-T, which targets multiple myeloma, diffuse large B-cell lymphoma, and mantle cell lymphoma by selectively inducing apoptosis by modulating eukaryotic, translation, initiation Factor 5A (eIF5A).

Senesco Technologies is the sponsor of the Phase 1b/2a study that is actively enrolling patients at Mayo Clinic in Rochester, Minnesota, the University of Arkansas for Medical Sciences in Little Rock, the Mary Babb Randolph Cancer Center in Morgantown, West Virginia, the John Theurer Cancer Center at Hackensack University Medical Center in Hackensack, New Jersey, and the Seattle Cancer Care Alliance in Seattle, Washington.

Senesco completed the second cohort of patients in their Phase 1b/2a clinical trial for the treatment of multiple myeloma, diffuse large B-cell lymphoma, and mantle cell lymphoma with SNS01-T. In cohort 2, two multiple myeloma patients and one diffuse large B-cell lymphoma patient completed the required number of doses to be evaluable from the total of 4 patients enrolled. As with the preceding dose level, there were no drug-related serious adverse events or dose-limiting toxicities in the evaluable patients or in the one patient who received only 5 infusions before being withdrawn. Over cohorts 1 and 2 at the two lowest dose levels, stabilization of serum monoclonal protein levels had been observed in three of the five evaluable multiple myeloma patients, and, in three of nine patients overall.

Senesco Technologies, Inc. (SNTI), closed Friday’s trading session at $0.0305, down 9.76%, on 881,740 volume with 34 trades. The average volume for the last 60 days is 2,056,916 and the stock's 52-week low/high is $0.019/$0.20.

El Capitan Precious Metals, Inc. (ECPN)

PennyTrader Publisher, AllPennyStocks, SmallCapVoice, PennyInvest, StockEgg, PennyStockVille, HotOTC, CoolPennyStocks, StockRich, MadPennyStocks, and BullRally reported earlier on El Capitan Precious Metals, Inc. (ECPN), and we report on the Company today, here at the QualityStocks Daily Newsletter.

El Capitan Precious Metals, Inc. is an exploration stage company chieflyengaging in the exploration of precious metals and other minerals. The Company mainlyholds interest in the El Capitan gold-silver property located near Capitan, New Mexico, in Lincoln County. El Capitan Precious Metals' principal asset is their wholly owned subsidiary El Capitan, Ltd., an Arizona corporation. This subsidiary holds the 100 percent equity interest in the El Capitan property.

The El Capitan property consists of 354 Bureau of Land Management (BLM) lode claims and four patented claims. The claim block occupies approximately 3,000 acres. The El Capitan deposit has been known as a potential iron ore resource for a number ofdecades. The U.S. Bureau of Mines drilled approximately 140 shallow holes through the outcropping, shallow-dipping magnetite skarn deposit in 1944 and 1948.

The El Capitan deposit is situated within a north-south-trending belt approximately 2 miles in width and 10 miles in area, which is underlain by Permian limestone and lesser quartz sandstone. Numerousrecovery methods have been used in extracting ore from the El Capitan property. These methods include the alkali fusion method, silver lead collection, and carbon pre-roast with silver-lead recovery.

El Capitan Precious Metals announced,at the end of February 2013, that they obtained results from a well-respected metallurgical lab that used pre-treatment of the ore and the industry accepted method of cyanide vat leaching. The resulting assays, obtained under "Chain of Custody" procedures, demonstrated significant values of gold along with lesser amounts of other precious metals.El Capitan announced this past June that their ore is undergoing analysis for the recovery values utilizing cyanide leaching.

The El Capitan deposit has a near-surface, pervasive nature.All of this occurs above the regional water table. This provides the potential for both a low mining cost and a long life operation.

El Capitan Precious Metals, Inc. (ECPN), closed Friday’s session at $0.11, up 11.11%, on 368,565 volume with 41 trades. The average volume for the last 60 days is 305,570 and the stock's 52-week low/high is $0.055/$0.1275.

Canyon Gold Corp. (CGCC)

Streetwise Reports reported earlier on Canyon Gold Corp. (CGCC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Founded in 2008, Canyon Gold Corp.is a gold exploration company. An exploration stage mining enterprise, Canyon Gold’s intention is to explore their claims for a large tonnage Carlin-type of gold deposit.The Company acquired 100 percent of the outstanding capital stock of Long Canyon Gold Resources Corp. in July of 2011.Long Canyon became their wholly owned subsidiary. Canyon Gold hasclaim holdings in the Long Canyon Trend - Spruce Ridge area.The Spruce Ridge, Nevada project is on the adjacent range immediately west of the recent Pequop Mountains, Long Canyon Trend major discovery by Fronteer Gold of a substantial Carlin-type gold deposit.Canyon Gold’s sharestrade on the OTC Bulletin Board. Their principal executive office is in Las Vegas, Nevada.

Canyon Gold and Long Canyon own and control a 100 percent interest in approximately 640 acres of mineral lease properties and/or approximately 30 BLM mineral lease claims in the west section of the new Long Canyon Gold Trend area of east central Nevada. The properties are held to explore for gold and silver mineralization deposits.

Long Canyon entered into an option agreement with EMAC Handels AG (EMAC) of Pfaeffikon, Switzerland in May of 2011. Upon exercise of the option, Long Canyon will acquire a 100 percent interest in approximately 6,250 acres of mineral lease properties and/or 275 Bureau of Land Management(BLM) mineral lease claims adjacent to Canyon Gold and Long Canyon's 30 claims. The Company and EMAC have occasionally entered into extension agreements and the option has currently been extended to December 31, 2013.

Canyon Gold hasengaged the services of Development Resources, LLC of American Fork, Utah to conduct preliminary studies of claims. Canyon Gold’s intention is to conduct exploration activities on the properties in phases. Their plan is to explore for gold, silver, as well as other minerals on the property covering an area of approximately 6,890 acres. This includes the acres subject to the option.

Canyon Gold Corp. (CGCC), closed Friday’s trading session at $0.29, up 190.00%, on 240,966 volume with 43 trades. The average volume for the last 60 days is 5,690 and the stock's 52-week low/high is $0.10/$0.75.

Universal Bioenergy, Inc. (UBRG)

Pastwellness.com, Stock Analyzer, Investor News Source, Stock Alerts, Pumps and Dumps, Stock Twiter, and Breaking News on Stock reported earlier on Universal Bioenergy, Inc. (UBRG), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Based in Irvine, California, Universal Bioenergy, Inc.is an independent diversified energy company. They produce and market natural gas, electricity, petroleum, coal, and propane. In addition, Universal Bioenergy engages in the acquisition and development of existing or recently discovered oil and gas fields, leases, and surface coal mines. The Company’s principalbusiness focus is the production, marketing, and sales of natural gas, oil, and alternative energy. 

Through their 49 percent owned subsidiary, NDR Energy Group, LLC, Universal Bioenergy currently sells natural gas to 29 of the largest public utilities, electric power producers, and local gas distribution companies. Theirstrategy and business plan is to be one of the foremost vertically integrated independent energy companies in the United States.

On February 28, 2012, Universal Bioenergy announced that they closed the transaction for the acquisition of a 40 percent stake in the Whitesburg Friday Branch Mine, LLC, a producer and provider of thermal steam coal in eastern Kentucky. With this acquisition, the Company expanded into the coal energy market sector.

Universal Bioenergy’s intention is to continue their growth through mergers and acquisitions of other companies in the natural gas, propane, petroleum, coal, and alternative energy industries. This may also include liquefied natural gas (LNG), compressed natural gas (CNG), biofuels, syngas, as well as acquisitions of patented energy technologies.

In late September,Universal Bioenergy announced that their subsidiary NDR Energy Group signed an agreement to supply electric power to one of the largest electric power utilities on the west coast. The new customer is a public utility, which provides energy service to 3.4 million people. The Customer's parent company is a Fortune 500 energy services company that provides electricity and natural gas services.On February 12, 2013, the Company announced that NDR Energy received final approval for their "Power Marketing License" from the Federal Energy Regulatory Commission (FERC). With this new contract, the Electric Power Division will now start to market electric power.

Universal Bioenergy, Inc. (UBRG), closed Friday at $0.0013, up 8.33%, on 17,952,175 volume with 42 trades. The average volume for the last 60 days is 7,545,236 and the stock's 52-week low/high is $0.0011/$0.012.

Liberty Coal Energy Corp. (LBTG)

VIP STOCK ALERTS, Stock Brain, HEROSTOCKS, Liquid Pennies, and Stockhunter.us reported earlier on Liberty Coal Energy Corp. (LBTG), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Denver, Colorado, Liberty Coal Energy Corp. is a resource development and production company. Their dedication is to the acquisition, development, and production of Clean Coals from the Wyoming, Great Plains, and Rocky Mountain regions.Clean Coal refers generally to a Low-sulfur coal. In general, this refers to a coal or a blend of coals that meets sulfur dioxide emission standards for air quality without the need for flue gas desulfurization.

The Company previously went by the name ESL Teachers, Inc. They changed their corporate name to Liberty Coal Energy Corp. in March 2010. Founded in 2007, Liberty Coal Energy’s shares trade on the OTCQB. The Company’schief business focus is to acquire and develop advanced coal properties in North America. The Company is currently holding one property, The Owsley Project in Owsley County, Kentucky.

Liberty Coal Energy’s Owsley property covers approximately 1,000 acres. This property has 3,600,000 tons of coal recoverable by surface and high wall (auger) methods. There are underground reserves in place which are not currently undergoing consideration for production. The Owsley project has a permit completed and technically approved by the Kentucky Department of Natural Resources for the first 80 acre phase.The permit can be placed on active status and mining started by posting a $175,000 reclamation bond. Liberty Cola Energy believes mining can commence within 90 days of breaking ground.

Liberty Coal Energy paid $15,000 downon June 13, 2013 toward the purchase of the Gamm Lease. The Gamm Lease is in Caddo Parrish, in Northwest Louisiana. The balance will be paid by way of a share transaction, not to exceed approximately $30,000. The property has electric power and some existing equipment on site. The Company’s plan is to test the next formation at approximately 2,500 feet with additional wells early in 2014. Additional shallow oil production opportunities exist in the immediate area that the Company is considering for participation. The Gamm Lease is a previous producing property. It contains nine shallow (+/- 1,700 ft.) production wells.

Liberty Coal Energy Corp. (LBTG), closed at $0.0011, up 37.50%, on 47,161,639 volume with 70 trades. The average volume for the last 60 days is 2,987,538 and the stock's 52-week low/high is $0.0005/$0.0975.

Amarantus Bioscience Holdings, Inc. (AMBS)

Greenbackers, PennyStocks24, Stock Analyzer, BUYINS.NET, SuperNova Elite, and First Penny Picks reported earlier on Amarantus Bioscience Holdings, Inc. (AMBS), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Sunnyvale, California, Amarantus Bioscience Holdings, Inc. isa biotechnology company centering on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis. The Company is developing certain biologics surrounding the intellectual property (IP) and proprietary technologies they own to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases.

Amarantus has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease. Amarantus owns the IP rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF). They are developing MANF-based products as treatments for brain disorders. Their lead therapeutic program MANF is a targeted therapeutic to address the underlying Programmed Cell Death (Apoptosis) associated with a widerangeof devastating human disorders.

Amarantus Bioscience is a Founding Member of the Coalition for Concussion Treatment (#C4CT). This movement started in collaboration with Brewer Sports International. They are working to raise awareness of new treatments in development for concussions and nervous-system disorders. In addition, Amarantus owns IP for the diagnosis of Parkinson's disease (NuroPro) and the discovery of neurotrophic factors (PhenoGuard).

This week,Amarantus Bioscience announced positive analytical performance data for the LymPro Test®, their flagship blood test for Alzheimer's disease. The data produced starts the process essentialto establish long-term analytical performance to support commercial launch in the second half of next year. It allows Amarantus to begin concentratingon the clinical performance data package the Company believes will be neededfor a successful product launch.

Mr. Gerald E. Commissiong, President & Chief Executive Officer of Amarantus Bioscience Holdings, said,“This data set begins the process of demonstrating that the assay, in our hands, is running to the same standards that were in place when positive clinical performance data was obtained and published. Now that we are establishing an assay with suitable analytical performance characteristics, we have begun the process of looking towards the clinical performance data we believe will ultimately determine the commercial success of LymPro. We believe LymPro has the potential to become a critical component in the diagnosis paradigm of Alzheimer's disease worldwide.”

Amarantus Bioscience Holdings, Inc. (AMBS), closed Friday’s session at $0.054, up 1.89%, on 3,082,275 volume with 161 trades. The average volume for the last 60 days is 6,122,083 and the stock's 52-week low/high is $0.0049/$0.195.

Press Ventures, Inc. (PVEN)

PickPennyStocks, Growing Stocks Reports, Michael Stone, Research Driven Alerts, Research Driven Investor, and Pumps and Dumps reported recently on Press Ventures, Inc. (PVEN), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Warsaw, Poland, Press Ventures, Inc.holds the worldwide rights to the patented Cedar Leaf Oil Diffusion (CLO-D) technology for the use of natural products to kill bacteria, mold, and viruses in buildings. The patented CLO-D technology has been shown to be capable of killing numerous deadly bacterial and viral substances including anthrax and H1N1 in buildings while they are still occupied. The Company’swholly-owned Polish subsidiary is Biosafety Systems, Inc. Sp z o.o. (BSI). Press Ventures’ shares trade on the OTCQB.

The CLO-D technology has been laboratory and field tested. Press Ventures believes that use of the technology can provide a noticeable improvement in air quality and eliminate many of the most dangerous airborne bacteria, viruses, and pollutants. 

Last week,Press Ventures, via Biosafety Systems (BSI), announced that they launched an online systems engineering application for their patented natural Cedar Leaf Oil Diffusion (CLO-D) bacteria and virus biosafety system on the BSI website.The newly designed online engineering application highlights and details the CLO-D biosafety system's features, advantages, and benefits, which allowsconsumers to choosewhich of the pre-engineered or custom configurations will best meet their distinctivebiosafety requirements.

This week,Press Ventures, through BSI,announced that they will be submitting their patented natural Cedar Leaf Oil Diffusion (CLO-D) bacteria and virus biosafety system to the National Institute of Hygiene (NIH) and National Institute of Public Health (NIPH) for testing in Poland. The design of the tests are to ascertainthe kinds of microorganisms in the CLO. If the independent laboratory analysis determines that the CLO contains no harmful pathogen microorganisms, a Statement of Certification will be issued.

Mr. Edward Denkiewicz, Press Ventures’ Chief Executive Officer, stated, “An endorsement from such a highly regarded European Union public health institution would send a clear signal to our potential customers and other biosafety market players that the CLO-D system and solutions developed and marketed by BSI can take a lead role in the fight against harmful airborne containments that plague human and animal habitats. Following a positive outcome of the NIH - NIPH testing, BSI expects to sell CLO-D biosafety systems in all sectors of the biosafety market, including agricultural, commercial, and residential.”

Press Ventures, Inc. (PVEN), closed Friday’s trading session at $0.147, up 9.70%, on 10,730,687 volume with 96 trades. The average volume for the last 60 days is 1,017,099 and the stock's 52-week low/high is $0.0016/$0.57.

ImageWare Systems, Inc. (IWSY)

Microcapmillionaires and TaglichBrothers reported earlier on ImageWare Systems, Inc. (IWSY), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

ImageWare Systems, Inc.is an identity innovator, which has provided advanced biometric solutions to traditional identity markets for over a decade. The Company is a foremost developer of mobile and cloud-based identity management solutions, providing biometric, secure credential, and law enforcement technologies. ImageWare Systems lists on the OTC Markets’ OTCQB. The Company has their corporate headquarters inSan Diego, California.

ImageWare’s biometric product line is scalable for global deployment.It includes a multi-biometric engine that is hardware and algorithm independent, allowingthe enrollment and management of unlimited population sizes. The Company’s identification products are used to manage and issue secure credentials, including national IDs, passports, driver's licenses, smart cards, and access control credentials. Their digital booking products provide law enforcement with integrated mug shot, fingerprint livescan and investigative capabilities.

The Company’s products include theirIWS Biometric Engine®. It is the first and only truly multi-modal, device- and algorithm- independent biometric software platform. Their recently re-engineered IWS Biometric Engine® 2.0, combines considerably enhanced performance and broader scalability with an SOA architecture.Therefore, this makes it possible to offer cloud-based biometric identity management services.

ImageWare also has their EPI Builder®. It provides the basis for a multi-modal biometric capture platform that ensures device interoperability and support for centralized and distributed deployment models. Additionally, the Company has theirGoCloudID.com. GoCloudID.com is a highly modular, SOA-based software platform that delivers a premier ability to quickly develop and deploy highly secure, yet flexible standards based identity solutions.These solutionsconstantly adapt to evolving customer requirements and emerging market demands.

ImageWare Systems is also using their proven multi-modal biometric advances to deliver ground-breaking mobile capabilities to the wireless, financial services, and healthcare sectors.The PillPhone®, enabled by the Company’s GoMobile interactive push application platform, is Food and Drug Administration (FDA) cleared and the only mobile health management application secured by biometrics.

Recently,ImageWare Systems announced that they received an order from the city of Fredericton, New Brunswick for a complete identity management and booking system; this includes mug photo, signature and fingerprint capture. The Company’s LE Web thin client will allow officers and administrative employees' access to record details and the full complementof investigative tools from differentlocations.

ImageWare Systems, Inc. (IWSY), closed Friday’s trading session at $2.02, up 18.82%, on 482,160 volume with 513 trades. The average volume for the last 60 days is 345,141 and the stock's 52-week low/high is $0.65/$2.85.


The QualityStocks
Company Corner


Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $3.75, up 1.63%, on 347,774 volume with 1000 trades. The stock’s average daily volume over the past 60 days is 32,155, and its 52-week low/high is $2.60/$19.375.

Advaxis Inc. today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Announces Full Exercise of Underwriters’ Over-Allotment Option

Advaxis Announces Pricing of Public Offering of Common Stock and Warrants

Advaxis Lead Product Candidate ADXS-HPV in Combination with PD-1 Antibody Significantly Improves Immune and Therapeutic Efficacy in Preclinical Study

NanoTech Entertainment, Inc. (NTEK)

The QualityStocks Daily Newsletter would like to spotlight NanoTech Entertainment, Inc. (NTEK). Today, NanoTech Entertainment, Inc. closed trading at $0.134, up 3.08%, on 3,811,763 volume with 320 trades. The stock’s average daily volume over the past 60 days is 5,341,546, and its 52-week low/high is $0.0005/$0.1485.

NanoTech Entertainment, Inc. announced today its Retention Sadler, Gibb and Associates LLC. Sadler, Gibb and Associates has previously provided services for NanoTech in the past and will be the audit firm for the company moving forward as it prepares to file audited financials in 2014. Jeff Foley, NanoTech CEO noted, “We have had a great relationship with Sadler, Gibb and really enjoy working with their team. They have a great dedicated team and already have a wonderful foundation with NanoTech making them the natural choice to work with us as we continue to expand.”

NanoTech Entertainment, Inc. (NTEK) is a conglomerate of entertainment companies focused on leveraging technology to deliver state-of-the-art entertainment and communications products. The company’s team is comprised of senior individuals who have been in the entertainment industry for more than 20 years and have a long track record of creating successful products.

Leveraging a diverse portfolio of products and technology, NanoTech is redefining the role of developers and manufacturers in the global market. The company has a unique business model with four technology business units focusing on gaming, media & IPTV, mobile apps, and manufacturing.

NanoTech’s Gaming Labs division operates as a virtual manufacturer, developing its technology and games, and licensing them to third parties for manufacturing and distribution in order to keep its overhead extremely low and operations efficient in the new global manufacturing economy. NanoTech Media develops proprietary technology which it licenses to publishers for use in their products as well as creating and publishing unique content. NanoTech Communications develops and sells proprietary apps and technology in the mobile and consumer space. Clear Memories is the global leader in 3D ice carving and manufacturing technology.

In a recent move to advance into the commercial media space, NanoTech signed a definitive agreement to acquire MagicScreen3D, a leader in the commercial implementation of glassless 3D screen technology. The company is focused on accelerating its corporate growth through additional acquisitions, licensing agreements, partnerships, and executing current business strategies. Leveraging its team’s expertise, NanoTech is well positioned to achieve greater success. Disclaimer

NanoTech Entertainment, Inc. Company Blog

NanoTech Entertainment, Inc. News:

NanoTech Entertainment Retains Sadler Gibb Audit Firm

NanoTech Entertainment Retains DME Law LLP for Hollywood Representation

NanoTech Entertainment Joins HDCP Licensee Group

Boston Therapeutics, Inc. (BTHE)

The QualityStocks Daily Newsletter would like to spotlight Boston Therapeutics, Inc. (BTHE). Today, Boston Therapeutics, Inc. closed trading at $1.57, up 25.60%, on 71,311 volume with 49 trades. The stock’s average daily volume over the past 60 days is 14,684, and its 52-week low/high is $0.15/$1.48.

Boston Therapeutics, Inc. (BTHE) is a pharmaceutical company focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs. An IP portfolio solidifies the company's position in the pharmaceutical industry. Boston Therapeutics' current product pipeline, PAZ320 and IPOXYNT, is comprised of therapies developed to treat patient populations with Type 2 diabetes.

PAZ320 is a non-systemic, non-toxic, chewable drug candidate for prevention of diabetes and its complications. PAZ320 inhibits the enzymes that release glucose from complex carbohydrate in foods during digestion. Boston Therapeutics believes PAZ320 is a safe and effective drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels, fulfilling an unmet medical need. PAZ320 has completed a Phase ll clinical trial at Dartmouth Medical Center. 45% of the patients responded with a 40% reduction in the elevation of post meal blood sugar compared to baseline with no serious adverse events.

IPOXYNT, a universal oxygen carrier, is an injectable Rx for prevention of necrosis and treatment of ischemic conditions which may lead to necrosis. This compound is not a biologic, but a second generation New Chemical Entity HBOC (hemoglobin based oxygen carrier). The potential for this product goes well beyond Lower Limb Ischemia into a range of areas from anemia and blood loss (injury), to cardiovascular disease and surgical blood supplementation.

The Boston Therapeutics management and advisory team has extensive expertise in complex carbohydrate chemistry, regulatory affairs, and clinical development, with multiple submissions and approvals to U.S. Food and Drug Administration. Backed by a team with more than five decades of expertise in public and private business management, the company is well positioned to advance its status as a premier developer of complex carbohydrate-based new chemical entities. Disclaimer

Boston Therapeutics, Inc. Company Blog

Boston Therapeutics, Inc. News:

Boston Therapeutics to Present at the Livingston Securities Advanced and Nano Life Sciences Summit

Boston Therapeutics Initiates Research Study on PAZ320 at University of Minnesota

Boston Therapeutics Closes $5.3 Million in Private Placement of Common Stock and Warrants

First Titan Corp. (FTTN)

The QualityStocks Daily Newsletter would like to spotlight First Titan Corp. (FTTN). Today, First Titan Corp. closed trading at $1.28, up 13.27%, on 181,199 volume with 166 trades. The stock’s average daily volume over the past 60 days is 70,154, and its 52-week low/high is $0.29/$3.75.

First Titan Corp. (FTTN), is currently focused on exploring and developing oil and natural gas resources in the southern region of the United Sates, but has a worldwide growth strategy in place. The company continually seeks to partner with energy developers that are pursuing innovative new methods of oil and gas extraction, including the development of new technologies, cleaner methods, and unconventional resources.

First Titan has acquired multiple working interests with established oil exploration companies to deliver new hydrocarbons to an ever-growing market. As the company maintains drilling activities at its acquisition in South Lake Charles, Louisiana, it is looking to continue adding to its asset base that includes five new wells along the Gulf Coast, from West Texas to Alabama.

Global demand for energy is rising fast as the vehicle populations of emerging nations such as China, Brazil, and India continue to soar. U.S. exports of petroleum products have reached 2.6 million barrels a day, which is double the level of three years ago. As demand for global energy resources rises, the U.S. is poised to become an international supplier.

New innovations in drilling and rising global demand have positioned First Titan as a premier early-stage company with strong growth potential. By utilizing cutting-edge technology to extract oil and gas resources, the company is able to recover fossil fuels that were once considered too difficult or too expensive to recover. Disclaimer

First Titan Corp. Company Blog

First Titan Corp. News:

FTTN Exploring Big Money Play in South Texas

FTTN Invests into Lucrative Gas-to-Liquids Market

FTTN Assets Positioned for Big Gains

CD International Enterprises, Inc. (CDII)

The QualityStocks Daily Newsletter would like to spotlight CD International Enterprises, Inc. (CDII). Today, CD International Enterprises, Inc. closed trading at $0.1139, up 5.95%, on 1,397,966 volume with 122 trades. The stock’s average daily volume over the past 60 days is 171,575, and its 52-week low/high is $0.041/$0.205.

CD International Enterprises, Inc. (CDII) is a U.S. based company that produces, sources, and distributes industrial commodities in China and the Americas, in addition to providing business and financial consulting services. Headquartered in Deerfield Beach, Florida, with corporate offices in Shanghai, CD International Enterprises’ unique infrastructure provides a platform to expand business opportunities globally.

Through its wholly owned subsidiary, International Magnesium Group, CD International Enterprises owns and operates one of the leading producers of magnesium in the world. International Magnesium Group sources its magnesium from six production facilities in the People's Republic of China, with a combined annual production and distribution capacity of approximately 80,000 metric tons of magnesium ingots and 10,000 metric tons of magnesium powder.

CD International Enterprises also sources, aggregates, and distributes iron ore, manganese ore, and scrap metals for companies located throughout the People’s Republic of China via wholly owned subsidiary CDII Minerals. The scope of CDII Minerals’ services include: purchasing, financing, logistics, quality control, in addition to conducting comprehensive legal, financial, and technical due diligence on suppliers.

The company’s management team possesses the necessary leadership expertise and a solid working knowledge of the unique characteristics of business operations in the U.S., China, Mexico, and South America. Employing a global growth strategy, CD International Enterprises has the unique ability to identify emerging market opportunities and provide comprehensive solutions or services relevant to conducting cross border business. Disclaimer

CD International Enterprises, Inc. Company Blog

CD International Enterprises, Inc. News:

CD International Subsidiary Completes Initial Shipments of Bolivian Iron Ore to a Leading Metals Trading Company in China

Minera MAPSA Completes Transfer of 178,000 Acres of Mining Concessions in Peru to CD International Enterprises Subsidiary

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of CD International Enterprises, Inc.

Raptor Resources Holdings Inc. (RRHI)

The QualityStocks Daily Newsletter would like to spotlight Raptor Resources Holdings Inc. (RRHI). Today, Raptor Resources Holdings Inc. closed trading at $0.024, up 20.00%, on 650 volume with 1 trade. The stock’s average daily volume over the past 60 days is 151,745, and its 52-week low/high is $0.0002/$0.0395.

Raptor Resources Holdings Inc. (RRHI) is a publicly traded holdings company focused on mineral resource acquisition, exploration, and development. The company currently has two subsidiaries: Mabwe Minerals Inc. (MBMI), a natural resources and hard asset company engaged in the mining and commercial sales of industrial minerals & metals with first focus on barite; and TAG Minerals Inc., a mineral & metal resource acquisition, exploration, and development company with first focus on alluvial surface gold.

Mabwe Minerals has been the focus of the parent company’s efforts the last two years to move into commercial barite production. RRHI shareholders share a common interest with MBMI shareholders in the success of Dodge Mine as the parent company owns 90M shares of MBMI. The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc.

TAG Minerals, along with its indigenous affiliate, TAG Minerals Zimbabwe (Private) Limited, is responsible for alluvial gold production along with the development of greenfield assets targeting bedrock gold and other potential metals & minerals. As MBMI is transitioning into commercial barite production, RRHI will now focus on building assets within TAG Minerals with the intent of moving into commercial production within the next 18 months. TAG Minerals will utilize the latest in Heavy Particle Concentrators (HPC-30/HPC-100) through its relationship with Extrac-TEC whose gold recovery and mineral separation technology captures up to 98% of alluvial gold down to 50 microns. The company is in early stage exploration evaluating potential alluvial sites to ensure they meet the company's criteria for commercial production. Coupled with MBMI's acquisition of WGB Kinsey & Company, TAG Minerals is well positioned to fast track into commercial production once the company has successfully completed its exploratory testing.

RRHI management continues to improve its balance sheet as reflected in the company's SEC 10k filing, including favorable reductions in the company's debt/liabilities and securing 54.4M shares and 14.4M warrants of RRHI from prior employees. The company is committed to growing its asset base in TAG Minerals moving forward. Disclaimer

Raptor Resources Holdings Inc. Company Blog

Raptor Resources Holdings Inc. News:

Mabwe Minerals Launches New Web Site as Affiliate Finalizes Barite Specification Sheets to Commence Barite Qualification

Mabwe Minerals Commences Mining Operations at Dodge Mine

Mabwe Minerals Frames Strategic Alliances With Steinbock Minerals Ltd. and Yasheya Ltd.

Ecrypt Technologies, Inc. (ECRY)

The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.18, up 0.56%, on $0.29/$3.75 volume with 2 trades. The stock’s average daily volume over the past 60 days is 15,678 and its 52-week low/high is $0.29/$3.75.

Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.

Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.

The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.

Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer

Ecrypt Technologies, Inc. Blog

Ecrypt Technologies, Inc. News:

Ecrypt Technologies, Inc. CEO Featured in Exclusive QualityStocks Interview

Ecrypt Focuses on Immediately Addressable Market

Ecrypt Technologies Receives Patent Pending Status

Max Sound Corp. (MAXD)

The QualityStocks Daily Newsletter would like to spotlight Max Sound Corp. (MAXD). Today, Max Sound Corp. closed trading at $0.233, up 0.87%, on 124,400 volume with 20 trades. The stock’s average daily volume over the past 60 days is 252,293, and its 52-week low/high is $0.165/$0.50.

Max Sound Corp. (MAXD) is an HD Audio Technology company with proprietary software that significantly improves the sound quality from virtually any digital or analog source - without increasing file size. Leveraging a strategic software licensing business model, MAX-D’s market is vast and includes improving recorded music, movies, audio books, live streaming, televised events, video games, television network programming, and all audio on mobile devices.

Through Max Sound’s recent acquisition of Liquid Spins, MAX-D has aligned its Technology with a significant audience who purchase music through smart devices. Liquid Spins is a digital media distribution company that has contracts with all major record labels in the United States, and specializes in targeted marketing strategies that focus on selling music in areas where music is not currently sold.

Backed by seasoned management, a competitive advantage, and strong intellectual properties, the company’s MAX-D Audio Process is poised to revolutionize the way consumers listen to media and communicate on their mobile devices. The MAX-D Technology restores audio to the highest quality in real time, while maximizing the output potential of virtually any device - without requiring any equipment change or upgrade in infrastructure.

Consumers have become unaware that they are listening to inferior compressed audio – in much the same way that HD television opened our eyes to a better picture quality, MAX-D opens our ears, to a realistic, true to life listening experience. MAX-D™ is Audio Perfected. Disclaimer

Max Sound Corp. Company Blog

Max Sound Corp. News:

Max Sound Corporation to Present at Singular's 8th Annual Best of the Uncovereds Conference

Max Sound Corporation CEO Featured in Equities.com Interview

MAX-D HD Audio Technology Debuts At Qualcomm's Uplinq 2013 Wireless Ecosystem Conference


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





Wall Street Profit Search



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251